Autoimmune hypoglycemia expands the biological spectrum of HHV8(+) multicentric Castleman disease

Autoimmune hypoglycemia belongs to the clinical spectrum of HHV8(+) MCD and rituximab is an effective treatment of this condition. This rare complication is related to autoantibodies directed toward the insulin receptor and activating the insulin signaling pathway.

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Arnautou, Pierre, Auclair, Martine, Fellahi, Soraya, Bouché, Clara, Fieschi, Claire, Barrak, Elias, Queyrel-Moranne, Viviane, Chaillous, Lucy, Blin, Nicolas, Malphettes, Marion, Fadlallah, Jehane, Bertinchamp, Remi, Gérard, Laurence, Bengoufa, Djaouida, Galicier, Lionel, Oksenhendler, Eric, Vigouroux, Corinne, Boutboul, David
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2021
Pynciau:
Stimulus Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045508/
https://ncbi.nlm.nih.gov/pubmed/33787862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002801
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg